What is InSphero?
InSphero is a specialized biotechnology enterprise that engineers sophisticated 3D cell culture and organ-on-a-chip systems. The company's core value proposition lies in its ability to generate human-like microtissues—including liver, tumor, and pancreatic models—that provide pharmaceutical researchers with high-fidelity data. By simulating complex biological environments, InSphero's technology enables more accurate disease biology studies and drug safety evaluations, effectively reducing the risks associated with clinical trials. This innovation is critical for the modern pharmaceutical industry, which is increasingly moving away from traditional 2D models toward more predictive, human-centric testing methodologies.
How much funding has InSphero raised?
InSphero has raised a total of $36.1M across 5 funding rounds:
Series A
$1.9M
Series B
$2.2M
Series C
$21.1M
Unspecified
$850K
Unspecified
$10M
Series A (2010): $1.9M with participation from Redalpine Venture Partners
Series B (2013): $2.2M, investors not publicly disclosed
Series C (2015): $21.1M, investors not publicly disclosed
Unspecified (2015): $850K, investors not publicly disclosed
Unspecified (2018): $10M backed by Venturelab
Key Investors in InSphero
Venturelab
Venturelab is a prominent Swiss organization dedicated to fostering entrepreneurship through specialized training and fundraising support for high-growth startups.
Redalpine Venture Partners
Redalpine is a thesis-driven venture capital firm that combines scientific expertise with operational experience to support disruptive, highly technical companies.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for InSphero?
With the recent capital secured, InSphero is well-positioned to accelerate its strategic roadmap, focusing on the commercialization of its high-throughput screening platforms. The company is expected to leverage this investment to deepen its integration into the drug discovery pipelines of major global pharmaceutical firms. Future growth will likely be driven by the expansion of its proprietary microtissue library and the refinement of its organ-on-a-chip systems to meet the increasing demand for personalized medicine and precision oncology. As the biotech industry continues to prioritize efficiency and accuracy in preclinical testing, InSphero's role as a foundational technology provider is set to strengthen, potentially leading to further strategic partnerships or future financing rounds to support global scaling efforts.
See full InSphero company page
